Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

ConclusionTreatment for 24  weeks with empagliflozin, in contrast to pioglitazone, was associated with improvement of liver steatosis and fibrosis in patients with NAFLD and T2DM. In addition, body weight and abdominal fat area were decreased in the empagliflozin group.Trial RegistrationIranian Registry of Clinical Trials (IRCT), IRCT20190122042450N3.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research